Bafna Pharmaceuticals Ltd
BAFNAPHBafna Pharmaceuticals Ltd
BAFNAPH
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 473.08 | 2.34 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.70 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 86.55 | 66.10 | 78.43 | 44.02 | 42.73 | 71.97 | 86.84 | 118.62 | 155.99 | 146.47 | ||||||||||
Raw Materials | 65.99 | 55.01 | 34.19 | 27.00 | 23.22 | 33.58 | 41.70 | 65.98 | 91.58 | 137.98 | ||||||||||
| Power & Fuel Cost | 2.38 | 2.01 | 2.12 | 2.50 | 2.69 | 2.95 | 3.93 | 5.31 | 6.73 | |||||||||||
| Employee Cost | 6.44 | 6.62 | 7.47 | 9.01 | 10.25 | 11.98 | 14.65 | 15.87 | 19.03 | |||||||||||
| Selling & Administrative Expenses | 3.30 | 3.15 | 4.07 | 3.13 | 3.18 | 2.67 | 6.92 | 5.39 | 13.98 | |||||||||||
| Operating & Other expenses | 4.39 | 3.39 | 34.40 | 15.06 | 25.22 | 9.74 | 8.14 | 7.09 | 10.03 | |||||||||||
EBITDA | 4.05 | -4.08 | -3.82 | -12.68 | -21.83 | 11.05 | 11.50 | 18.98 | 14.64 | 8.49 | ||||||||||
| Depreciation/Amortization | 4.11 | 3.89 | 3.65 | 3.42 | 3.27 | 4.48 | 5.49 | 5.33 | 5.00 | 5.56 | ||||||||||
| PBIT | -0.06 | -7.97 | -7.47 | -16.10 | -25.10 | 6.57 | 6.01 | 13.65 | 9.64 | 2.93 | ||||||||||
| Interest & Other Items | 12.47 | 11.34 | 6.81 | 2.13 | 0.10 | 0.74 | 0.79 | 2.04 | 2.29 | 2.53 | ||||||||||
| PBT | -12.53 | -19.31 | -14.28 | -18.23 | -25.20 | 5.83 | 5.22 | 11.61 | 7.35 | 0.40 | ||||||||||
| Taxes & Other Items | -0.34 | -0.84 | 2.18 | 1.50 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 | — | ||||||||||
| Net Income | -12.19 | -18.47 | -16.46 | -19.73 | -25.20 | 5.83 | 5.22 | 11.33 | 7.35 | 0.40 | ||||||||||
| EPS | -6.53 | -9.90 | -7.78 | -8.34 | -19.37 | 4.48 | 2.21 | 4.79 | 3.11 | 0.17 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bafna Pharmaceuticals Ltd | 25.75 | 2.34 | — |
| Sun Pharmaceutical Industries Ltd | 44.52 | 6.35 | 0.76% |
| Cipla Ltd | 28.83 | 4.43 | 0.88% |
| Torrent Pharmaceuticals Ltd | 63.23 | 15.28 | 0.90% |
Price Comparison
Compare BAFNAPH with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
BAFNAPH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2013
Dividend/Share
₹0.60
Ex DateEx Date
Sep 19, 2013
Net profit of Bafna Pharmaceuticals rose 5.65% to Rs 2.62 crore in the quarter ended September 2024 as against Rs 2.48 crore during the previous quarter ended September 2023. Sales declined 0.88% to Rs 40.32 crore in the quarter ended September 2024 as against Rs 40.68 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales40.3240.68 -1 OPM %9.429.83 - PBDT4.203.72 13 PBT2.622.48 6 NP2.622.48 6 Powered by Capital Market - Live
Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live
Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
Net loss of Bafna Pharmaceuticals reported to Rs 0.72 crore in the quarter ended June 2024 as against net profit of Rs 6.35 crore during the previous quarter ended June 2023. Sales declined 20.64% to Rs 33.29 crore in the quarter ended June 2024 as against Rs 41.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.2941.95 -21 OPM %3.6314.99 - PBDT1.077.56 -86 PBT-0.376.35 PL NP-0.726.35 PL Powered by Capital Market - Live
Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y
Bafna Pharmaceuticals standalone net profit rises 88.89% in the December 2021 quarter
Bafna Pharma in talks with multinational pharma firms for brand acquisition
In talks with MNCs pharma cos for acquisition of brands: Bafna pharma
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 28.79%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0.02% to 0.04%